Capital Research Global Investors Cuts Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Capital Research Global Investors cut its DexCom stake by 56.2% in Q3, selling 3,038,943 shares and now holds 2,367,676 shares (~0.61% of the company) valued at about $159.3 million.
• At the same time, other large institutions (Legal & General, Schroder, Korea Investment, First Trust) increased or initiated positions, leaving institutional ownership at roughly 97.75%.
• Analyst sentiment remains broadly positive—Citigroup raised its price target to $84 and MarketBeat’s consensus is a “Moderate Buy” with an $85.50 target—after DexCom reported an earnings beat and 13.1% year‑over‑year revenue growth.

Capital Research Global Investors reduced its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 56.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,367,676 shares of the medical device company's stock after selling 3,038,943 shares during the period. Capital Research Global Investors owned about 0.61% of DexCom worth $159,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Legal & General Group Plc grew its position in shares of DexCom by 4.7% during the 3rd quarter. Legal & General Group Plc now owns 2,635,700 shares of the medical device company's stock valued at $177,356,000 after acquiring an additional 117,493 shares during the period. Bell Asset Management Ltd purchased a new position in DexCom during the third quarter worth approximately $2,116,000. Schroder Investment Management Group grew its holdings in DexCom by 274.7% in the third quarter. Schroder Investment Management Group now owns 149,606 shares of the medical device company's stock valued at $10,067,000 after purchasing an additional 109,675 shares during the period. Korea Investment CORP grew its holdings in DexCom by 103.0% in the third quarter. Korea Investment CORP now owns 769,664 shares of the medical device company's stock valued at $51,791,000 after purchasing an additional 390,501 shares during the period. Finally, First Trust Advisors LP increased its position in shares of DexCom by 19.3% in the third quarter. First Trust Advisors LP now owns 1,014,459 shares of the medical device company's stock valued at $68,263,000 after buying an additional 163,818 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $66.31 on Thursday. The firm has a 50-day simple moving average of $70.73 and a 200-day simple moving average of $68.55. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $25.52 billion, a price-to-earnings ratio of 31.58, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the business posted $0.45 earnings per share. DexCom's quarterly revenue was up 13.1% on a year-over-year basis. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Citigroup raised its price target on DXCM from $77 to $84 and kept a "buy" rating — a notable analyst upgrade that implies roughly 27% upside from the current price. Citigroup price target raise (Benzinga)
• Positive Sentiment: BTIG issued a "Buy" rating on DexCom, adding to the recent wave of buy-side analyst support. BTIG Buy Rating (American Banking News)
• Positive Sentiment: DexCom presented clinical outcomes and outlined its product roadmap at the ATTD 2026 conference in Barcelona — product pipeline/detail disclosures are typically viewed positively for long-term growth prospects. ATTD 2026 presentation (Business Wire)
• Positive Sentiment: The Motley Fool included DexCom among long-term growth stock picks, reinforcing a buy-and-hold narrative for investors focused on multi-year gains. Long-term growth stock mention (Fool)
• Neutral Sentiment: Benzinga ran a roundup of 12 analyst reviews on DexCom that provides mixed analyst perspectives and consensus context — useful for gauging sentiment but not a single-direction catalyst. Analyst reviews roundup (Benzinga)
• Neutral Sentiment: MarketWatch noted DexCom outperformed some competitors on the day despite broader losses — a relative-strength datapoint but not a direct directional driver. Relative performance note (MarketWatch)
• Neutral Sentiment: Reported spikes in short interest appear in the data feeds, but the published entries show zero shares / NaN changes — this looks like a data error and should not be treated as confirmed bearish pressure until clarified by exchanges. (Data entry from March filings)

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Citigroup upped their target price on DexCom from $77.00 to $84.00 and gave the stock a "buy" rating in a research note on Wednesday. Piper Sandler reissued an "overweight" rating on shares of DexCom in a report on Thursday, February 5th. BTIG Research restated a "buy" rating and set a $85.00 price objective on shares of DexCom in a research report on Monday. Robert W. Baird set a $87.00 price objective on shares of DexCom in a report on Friday, February 13th. Finally, Weiss Ratings raised shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $85.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.